Literature DB >> 1544906

Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil.

D J Porter1, W G Chestnut, B M Merrill, T Spector.   

Abstract

Uracil analogues with appropriate substituents at the 5-position inactivated dihydropyrimidine dehydrogenase (DHPDHase). The efficiency of these inactivators was highly dependent on the size of the 5-substituent. For example, 5-ethynyluracil inactivated DHPDHase with an efficiency (kinact/Ki) that was 500-fold greater than that for 5-propynyluracil. 5-Ethynyluracil inactivated DHPDHase by initially forming a reversible complex with a Ki of 1.6 +/- 0.2 microM. This initial complex yielded inactivated enzyme with a rate constant of 20 +/- 2 min-1 (kinact). Thymine competitively decreased the apparent rate constant for inactivation of DHPDHase by 5-ethynyluracil. The absorbance spectrum of 5-ethylnyluracil-inactivated DHPDHase was different from that of reduced enzyme. These optical changes were correlated with the loss of enzymatic activity. 5-Ethynyluracil inactivated DHPDHase with a stoichiometry of 0.9 mol of inactivator per mol of active site. Enzyme inactivated with [2-14C]5-ethynyluracil retained all of the radiolabel after denaturation in 8 M urea, but lost radiolabel under acidic conditions. These results suggested that inactivation was due to covalent modification of an amino acid residue and not due to modification of a noncovalently bound prosthetic group. A radiolabeled peptide was isolated from a tryptic digest of the enzyme inactivated with [2-14C]5-ethynyluracil. The sequence of this peptide was Lys-Ala-Glu-Ala-Ser-Gly-Ala-Y-Ala-Leu-Glu-Leu-Asn-Leu-Ser-X-Pro-His-Gly- Met-Gly-Glu-Arg, where X and Y were unidentified amino acids. Since the radiolabel was lost from the peptide during the first cycle on the amino acid sequenator, the position of the radiolabeled amino acid was not determined. The amino acid residue designated by X was identified as a cysteine from previous work with DHPDHase inactivated with 5-iodouracil. In contrast to 5-ethynyluracil, 5-cyanouracil was a reversible inactivator of the enzyme. 5-Cyanouracil-inactivated enzyme slowly regained activity (t1/2 = 1.8 min) after dilution into the standard assay. DHPDHases isolated from rat, mouse, and human liver had similar sensitivities to inactivation by 5-alkynyluracils.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1544906

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  [Ru(bpy)2(5-cyanouracil)2]2+ as a potential light-activated dual-action therapeutic agent.

Authors:  Robert N Garner; Judith C Gallucci; Kim R Dunbar; Claudia Turro
Journal:  Inorg Chem       Date:  2011-08-31       Impact factor: 5.165

Review 2.  Progress in colorectal cancer chemotherapy: how far have we come, how far to go?

Authors:  M E Royce; P M Hoff; R Pazdur
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

Review 3.  Pharmacology of fluorinated pyrimidines: eniluracil.

Authors:  S D Baker
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

Review 4.  Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.

Authors:  M T Paff; D P Baccanari; S T Davis; S Cao; R L Tansik; Y M Rustum; T Spector
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

Review 5.  Novel oral chemotherapy agents.

Authors:  M E Royce; P M Hoff; R Pazdur
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

Review 6.  Novel chemotherapy agents for colorectal cancer: oral fluoropyrimidines, oxaliplatin, and raltitrexed.

Authors:  M E Royce; P M Hoff; R Padzur
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

7.  Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil.

Authors:  D Dobritzsch; G Schneider; K D Schnackerz; Y Lindqvist
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

Review 8.  A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.

Authors:  A A Adjei
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

9.  Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.

Authors:  Sherry Morgan-Meadows; James P Thomas; Daniel Mulkerin; Jordan D Berlin; Howard Bailey; Kim Binger; Jennifer Volkman; Dona Alberti; Chris Feierabend; Rebecca Marrocha; Rhoda Z Arzoomanian; George Wilding
Journal:  Invest New Drugs       Date:  2002-11       Impact factor: 3.850

10.  5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.

Authors:  D P Baccanari; S T Davis; V C Knick; T Spector
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.